Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TERN
stocks logo

TERN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.307
+27.98%
--
--
-0.312
+19.87%
--
--
-0.327
+25.64%
Estimates Revision
The market is revising No Change the revenue expectations for Terns Pharmaceuticals, Inc. (TERN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 275.76%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+275.76%
In Past 3 Month
Wall Street analysts forecast TERN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TERN is 25.00 USD with a low forecast of 15.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast TERN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TERN is 25.00 USD with a low forecast of 15.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 27.130
sliders
Low
15.00
Averages
25.00
High
35.00
Current: 27.130
sliders
Low
15.00
Averages
25.00
High
35.00
Citizens JMP
Outperform
maintain
$25 -> $35
2025-11-26
Reason
Citizens JMP
Price Target
$25 -> $35
2025-11-26
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Terns Pharmaceuticals to $35 from $25 and keeps an Outperform rating on the shares. Terns's ASH abstract showed that TERN-701 delivered an unprecedented 24-week major molecular response rate in 2L+ relapsed/refractory chronic myeloid leukemia, outperforming other Phase 1 CML therapies in efficacy and tolerability, the analyst tells investors in a research note. Feedback from key opinion leaders suggests the drug is on a best-in-class trajectory with real potential to move into the front-line setting, the firm says.
Barclays
Etzer Darout
Overweight
maintain
$28 -> $36
2025-11-25
Reason
Barclays
Etzer Darout
Price Target
$28 -> $36
2025-11-25
maintain
Overweight
Reason
Barclays analyst Etzer Darout raised the firm's price target on Terns Pharmaceuticals to $36 from $28 and keeps an Overweight rating on the shares. The company is converting to a patient based model for TERN-701 and the drug has the potential to take significant share of the chronic myeloid leukemia market, the analyst tells investors in a research note.
BMO Capital
Outperform
maintain
$22 -> $30
2025-11-18
Reason
BMO Capital
Price Target
$22 -> $30
2025-11-18
maintain
Outperform
Reason
BMO Capital raised the firm's price target on Terns Pharmaceuticals to $30 from $22 and keeps an Outperform rating on the shares. The opportunity for TERN-701 in CML remains underappreciated as Phase 1 CARDINAL abstract data has been clearly differentiated against existing therapies, the analyst tells investors in a research note.
Mizuho
Graig Suvannavejh
Outperform
maintain
$32 -> $33
2025-11-13
Reason
Mizuho
Graig Suvannavejh
Price Target
$32 -> $33
2025-11-13
maintain
Outperform
Reason
Mizuho analyst Graig Suvannavejh raised the firm's price target on Terns Pharmaceuticals to $33 from $32 and keeps an Outperform rating on the shares following the Q3 report.
Barclays
NULL -> Overweight
maintain
$27 -> $28
2025-11-11
Reason
Barclays
Price Target
$27 -> $28
2025-11-11
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Terns Pharmaceuticals to $28 from $27 and keeps an Overweight rating on the shares following the Q3 report.
H.C. Wainwright
Andrew Fein
Neutral -> Buy
upgrade
$20
2025-11-04
Reason
H.C. Wainwright
Andrew Fein
Price Target
$20
2025-11-04
upgrade
Neutral -> Buy
Reason
H.C. Wainwright analyst Andrew Fein upgraded Terns Pharmaceuticals to Buy from Neutral with a $20 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Terns Pharmaceuticals Inc (TERN.O) is -20.74, compared to its 5-year average forward P/E of -4.83. For a more detailed relative valuation and DCF analysis to assess Terns Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.83
Current PE
-20.74
Overvalued PE
-2.00
Undervalued PE
-7.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.93
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.43
Undervalued EV/EBITDA
-5.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.49
Current PS
0.00
Overvalued PS
55.76
Undervalued PS
-34.79
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 5858.69% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 5858.69% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TERN News & Events

Events Timeline

(ET)
2025-11-10
16:25:08
Terns Pharmaceuticals announces Q3 earnings per share of 27 cents, below consensus estimate of 30 cents.
select
2025-11-03 (ET)
2025-11-03
09:19:44
Terns Pharmaceuticals reveals findings from the CARDINAL trial of TERN-701.
select
2025-10-22 (ET)
2025-10-22
05:22:53
Terns Pharmaceuticals announces 12-week findings from TERN-601 study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-26Benzinga
Broadcom Set to Surge by 13%? Check Out 10 Leading Analyst Predictions for Wednesday

  • Analyst Rating Changes: Keybanc, Evercore ISI, Bernstein, and Deutsche Bank made notable adjustments to price targets for various companies, including Workday, Kohl's, Zscaler, and Autodesk, while maintaining their respective ratings.

  • Price Target Increases: Companies like Kohl's, Zscaler, Autodesk, and Theravance Biopharma saw their price targets raised, indicating positive outlooks from analysts despite current share prices.

  • Price Target Decreases: Nutanix experienced a significant cut in its price target by B of A Securities, although the analyst maintained a Buy rating, reflecting mixed sentiments in the market.

  • Overall Market Sentiment: Analysts from firms like Goldman Sachs and B of A Securities expressed optimism for stocks like Broadcom and Dell, raising their price targets while maintaining positive ratings.

[object Object]
Preview
6.0
11-26Benzinga
Citizens Upgrades Terns Pharma to Market Outperform and Increases Price Target to $35

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

[object Object]
Preview
4.0
11-20Benzinga
Truist Securities Reaffirms Buy Rating for Terns Pharma and Increases Price Target to $35

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing collaboration and information sharing.

  • Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Terns Pharmaceuticals Inc (TERN) stock price today?

The current price of TERN is 27.13 USD — it has decreased -1.31 % in the last trading day.

arrow icon

What is Terns Pharmaceuticals Inc (TERN)'s business?

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

arrow icon

What is the price predicton of TERN Stock?

Wall Street analysts forecast TERN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TERN is 25.00 USD with a low forecast of 15.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Terns Pharmaceuticals Inc (TERN)'s revenue for the last quarter?

Terns Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Terns Pharmaceuticals Inc (TERN)'s earnings per share (EPS) for the last quarter?

Terns Pharmaceuticals Inc. EPS for the last quarter amounts to -0.27 USD, decreased -3.57 % YoY.

arrow icon

What changes have occurred in the market's expectations for Terns Pharmaceuticals Inc (TERN)'s fundamentals?

The market is revising No Change the revenue expectations for Terns Pharmaceuticals, Inc. (TERN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 275.76%.
arrow icon

How many employees does Terns Pharmaceuticals Inc (TERN). have?

Terns Pharmaceuticals Inc (TERN) has 59 emplpoyees as of December 05 2025.

arrow icon

What is Terns Pharmaceuticals Inc (TERN) market cap?

Today TERN has the market capitalization of 2.44B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free